Evidence map›Paper›PMID 35621770›Full record

ArticleInsects2022

Strain Characterisation for Measuring Bioefficacy of ITNs Treated with Two Active Ingredients (Dual-AI ITNs): Developing a Robust Protocol by Building Consensus.

Rosemary S Lees, Jennifer S Armistead, Salum Azizi, Edi Constant, Christen Fornadel, John E Gimnig, Janet Hemingway, Daniel Impoinvil, Seth R Irish, William Kisinza and 13 more

Abstract readConsensus Statement
In one paragraph

Article in Insects, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Susceptibility ofCurrent research in parasitology & vector-borne diseases · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Rosemary S LeesDepartment of Vector Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.ORCID 0000-0002-4232-9125
Jennifer S ArmisteadU.S. President's Malaria Initiative (PMI), U.S. Agency for International Development (USAID), Washington, DC 20547, USA.ORCID 0000-0002-0542-6401
Salum AziziKCMUCo-PAMVERC Test Facility, Department of Medical Parasitology and Entomology, Kilimanjaro Christian Medical University College, Moshi P.O. Box 2240, Tanzania.
Edi ConstantCentre Suisse de Recherches Scientifiques (CSRS), Abidjan 1303, Côte d'Ivoire.
Christen FornadelInnovative Vector Control Consortium (IVCC), Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.
John E GimnigDivision of Parasitic Diseases and Malaria, Centers for Disease Control (CDC) and Prevention, Atlanta, GA 30329, USA.
Janet HemingwayDepartment of Vector Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.
Daniel ImpoinvilDivision of Parasitic Diseases and Malaria, Centers for Disease Control (CDC) and Prevention, Atlanta, GA 30329, USA.
Seth R IrishU.S. President's Malaria Initiative (PMI), Centers for Disease Control (CDC) and Prevention, Atlanta, GA 30329, USA.
William KisinzaAmani Research Centre, National Institute for Medical Research, Muheza P.O. Box 81, Tanzania.ORCID 0000-0001-7073-186X
Natalie LissendenDepartment of Vector Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.ORCID 0000-0002-6578-5537
Henry D MawejjeInfectious Diseases Research Collaboration (IDRC), Plot 2C Nakasero Hill Road, Kampala P.O. Box 7475, Uganda.
Louisa A MessengerDepartment of Disease Control, Faculty of Infectious Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.ORCID 0000-0002-3107-6214
Sarah MooreVector Control Product Testing Unit (VCPTU), Environmental Health and Ecological Science Department, Ifakara Health Institute, Bagamoyo P.O. Box 74, Tanzania.ORCID 0000-0002-0938-6654
Corine NguforDepartment of Disease Control, Faculty of Infectious Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.ORCID 0000-0002-7755-9609
Richard OxboroughPMI VectorLink Project, Abt Associates, 6130 Executive Blvd., Rockville, MD 20852, USA.
Natacha ProtopopoffDepartment of Disease Control, Faculty of Infectious Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
Hilary RansonDepartment of Vector Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.ORCID 0000-0003-2332-8247
Graham SmallInnovative Vector Control Consortium (IVCC), Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.
Joseph WagmanMalaria and Neglected Tropical Diseases Program, PATH, Washington, DC 20001, USA.ORCID 0000-0002-5178-3098
David WeetmanDepartment of Vector Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.ORCID 0000-0002-5820-1388
Sarah ZohdyDivision of Parasitic Diseases and Malaria, Centers for Disease Control (CDC) and Prevention, Atlanta, GA 30329, USA.
Angus SpiersInnovation to Impact, Pembroke Place, Liverpool L3 5QA, UK.

Funding

Medical Research Council MR/R006040/1
6 · The paper itself

Abstract

Durability monitoring of insecticide-treated nets (ITNs) containing a pyrethroid in combination with a second active ingredient (AI) must be adapted so that the insecticidal bioefficacy of each AI can be monitored independently. An effective way to do this is to measure rapid knock down of a pyrethroid-susceptible strain of mosquitoes to assess the bioefficacy of the pyrethroid component and to use a pyrethroid-resistant strain to measure the bioefficacy of the second ingredient. To allow robust comparison of results across tests within and between test facilities, and over time, protocols for bioefficacy testing must include either characterisation of the resistant strain, standardisation of the mosquitoes used for bioassays, or a combination of the two. Through a series of virtual meetings, key stakeholders and practitioners explored different approaches to achieving these goals. Via an iterative process we decided on the preferred approach and produced a protocol consisting of characterising mosquitoes used for bioefficacy testing before and after a round of bioassays, for example at each time point in a durability monitoring study. We present the final protocol and justify our approach to establishing a standard methodology for durability monitoring of ITNs containing pyrethroid and a second AI.

Indexed as

bioefficacydual active ingredients (dual-AI)durability monitoringinsecticide resistanceinsecticide-treated nets (ITN)method developmentmosquitoproduct evaluationpyrethroidquality control (QC)strain characterisation

Identifiers

PMID35621770
PMCPMC9144861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.